Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563917 | 0.83 | CARM1 (0.49) | KLKB1 | |
| SCHEMBL7229018 | 0.81 | F10 (0.45) | KLKB1F10 | |
| SCHEMBL7230395 | 0.79 | KDM4E (0.48) | LMNAPOLBALDH1A1HPGDKDM4E | |
| SCHEMBL7230019 | 0.77 | KDM4E (0.44) | POLBNR3C2ALDH1A1HPGDKDM4E | |
| SCHEMBL5070346 | 0.74 | ADORA3 (0.41) | LMNAPOLBADORA3ALDH1A1HPGD | |
| SCHEMBL4564047 | 0.74 | ADORA3 (0.41) | LMNAPOLBADORA3ALDH1A1HPGD | |
| SCHEMBL7239926 | 0.74 | MAPT (0.46) | POLBALDH1A1HPGDKDM4ETSHR | |
| SCHEMBL5064194 | 0.74 | ADORA3 (0.42) | LMNAPOLBADORA2AADORA3ALDH1A1 | |
| SCHEMBL5064195 | 0.74 | ADORA3 (0.42) | LMNAPOLBADORA2AADORA3ALDH1A1 | |
| SCHEMBL5069680 | 0.74 | ADORA3 (0.42) | LMNAPOLBADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548525-B2 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| US-6271237-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-1999032454-A9 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARM CO (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1042299-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032454-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | F12, F11, F2 | LMNA 1138/4885POLB 3078/4885ADORA2A 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.